[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509373":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":40,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":62,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Jiangsu Cancer Institute & Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Observation Group",null,[12],"Radiation: Intensity modulated radiation therapy (IMRT) combined with chemotherapy",[14],{"type":15,"name":16,"description":16,"armGroupLabels":17,"otherNames":18},"RADIATION","Intensity modulated radiation therapy (IMRT) combined with chemotherapy",[9],[19],"IMRT",[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Lirong Wu","CONTACT","+86-13701588737","wulirong126@126.com",[27],{"facility":28,"status":10,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Jiangsu Cancer Hospital","Nanjing","China","CN",{"type":33,"coordinates":34},"Point",[35,36],118.77778,32.06167,{"lat":36,"lon":35},[39],{"name":22,"role":23,"phone":10,"phoneExt":10,"email":25},{"type":41,"investigatorFullName":22,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Associate Professor","100509373","prospective-study-for-molecular-biomarkers-and-spatial-transcriptomics-of-nasopharyngeal-carcinoma-100509373",false,"NCT05912582","Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Patients with newly histologically confirmed nasopharyngeal carcinoma\n2. No evidence of distant metastasis (M0)\n3. Written informed consent\n\nExclusion Criteria:\n\nTreatment with palliative intent","ALL","18 Years","80 Years",{"count":53,"type":54},60,"ESTIMATED","OBSERVATIONAL","This clinical research aims to explore potential biomarkers and validate molecular signatures' predictive and prognostic value in nasopharyngeal carcinoma.",[58],"Nasopharyngeal Carcinoma",[58,60,61],"Biomarker","Spatial Transcriptomics","NOT_YET_RECRUITING","2025-12-19",{"date":65,"type":66},"2025-12-26","ACTUAL",{"date":68,"type":54},"2025-12-25",{"date":70,"type":54},"2028-12-25",{"name":5,"class":6},1]